Changes in Hong Kong stocks | Xiansheng Pharmaceutical (02096) rose more than 2% and Lingke Pharmaceutical reached further cooperation on the selective JAK1 inhibitor zeprixitinib

The Zhitong Finance App learned that Xiansheng Pharmaceutical (02096) rose more than 2%. As of press release, it had risen 1.96% to HK$10.39, with a turnover of HK$25.217,200.

According to the news, Xiansheng Pharmaceutical announced that on November 2, 2026, the Group and Lingke Pharmaceutical (Zhejiang) Co., Ltd. (Lingke Pharmaceutical) reached further cooperation on the selective JAK1 inhibitor zeprixitinib. The Group will receive exclusive commercial rights in mainland China, Hong Kong, Macao and Taiwan for moderate to severe atopic dermatitis (AD) and other dermatological indications in adults.

The Group and Linke Pharmaceuticals reached a cooperation in March 2022 to obtain exclusive commercialization rights for rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in mainland China, Hong Kong, Macao and Taiwan. This cooperation will further expand the commercialization potential of zeprixitinib and improve the Group's product layout in the field of autoimmune diseases. In addition, a phase III clinical study of zepximitinib to treat rheumatoid arthritis has been completed, and a phase III clinical development project for ankylosing spondylitis is ongoing.